Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy - Initial patient care and outcome data

Kimber Debelak, William R. Morrone, Kevin E. O'Grady, Hendrée E. Jones

Research output: Contribution to journalArticle

Abstract

Background and Objectives Research has indicated that the buprenorphine-mono product yields maternal outcomes similar to methadone and a less severe neonatal abstinence syndrome. However, maternal and neonatal outcomes following buprenorphine + naloxone exposure during pregnancy have not been documented. Methods Retrospective chart review identified 10 opioid-dependent pregnant women treated with the buprenorphine + naloxone film product between January, 2010-June, 2011. Seven maternal outcome measures - weight gain, fetal presentation at delivery, Cesarean delivery, analgesia during delivery, urine drug screening results at delivery, number of days of maternal hospital stay, and began breastfeeding following delivery - and eleven neonatal outcome measures - gestational age at delivery, 1- and 5-minute Apgar scores, head circumference, length, and weight at birth, treated for neonatal abstinence syndrome (NAS), total amount of morphine sulfate needed to treat NAS, length of hospital stay for NAS treatment, and length of hospital stay - were extracted from medical records. Results Maternal findings were unremarkable, and comparable with what might be found following treatment with the buprenorphine-mono product. Neonates were full-term with normal birth parameters. Four neonates were treated for NAS, and number of days treated for NAS and number of hospital days were in line with values reported for the buprenorphine-mono product. Conclusions Findings suggest no obvious significant adverse maternal or neonatal outcomes related to the use of buprenorphine + naloxone for the treatment of opioid dependence during pregnancy. Scientific Significance These initial findings underscore the need for future research to systematically examine the relative safety and effectiveness of buprenorphine + naloxone for mother, fetus, and child.

Original languageEnglish (US)
Pages (from-to)252-254
Number of pages3
JournalAmerican Journal on Addictions
Volume22
Issue number3
DOIs
StatePublished - May 2013

Fingerprint

Neonatal Abstinence Syndrome
Opioid Analgesics
Patient Care
Mothers
Pregnancy
Length of Stay
Buprenorphine
Therapeutics
Labor Presentation
Outcome Assessment (Health Care)
Newborn Infant
Preclinical Drug Evaluations
Apgar Score
Methadone
Naloxone Drug Combination Buprenorphine
Breast Feeding
Birth Weight
Analgesia
Morphine
Gestational Age

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy - Initial patient care and outcome data. / Debelak, Kimber; Morrone, William R.; O'Grady, Kevin E.; Jones, Hendrée E.

In: American Journal on Addictions, Vol. 22, No. 3, 05.2013, p. 252-254.

Research output: Contribution to journalArticle

Debelak, Kimber ; Morrone, William R. ; O'Grady, Kevin E. ; Jones, Hendrée E. / Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy - Initial patient care and outcome data. In: American Journal on Addictions. 2013 ; Vol. 22, No. 3. pp. 252-254.
@article{3fc69165c7a94268a5c5b23ef302efa5,
title = "Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy - Initial patient care and outcome data",
abstract = "Background and Objectives Research has indicated that the buprenorphine-mono product yields maternal outcomes similar to methadone and a less severe neonatal abstinence syndrome. However, maternal and neonatal outcomes following buprenorphine + naloxone exposure during pregnancy have not been documented. Methods Retrospective chart review identified 10 opioid-dependent pregnant women treated with the buprenorphine + naloxone film product between January, 2010-June, 2011. Seven maternal outcome measures - weight gain, fetal presentation at delivery, Cesarean delivery, analgesia during delivery, urine drug screening results at delivery, number of days of maternal hospital stay, and began breastfeeding following delivery - and eleven neonatal outcome measures - gestational age at delivery, 1- and 5-minute Apgar scores, head circumference, length, and weight at birth, treated for neonatal abstinence syndrome (NAS), total amount of morphine sulfate needed to treat NAS, length of hospital stay for NAS treatment, and length of hospital stay - were extracted from medical records. Results Maternal findings were unremarkable, and comparable with what might be found following treatment with the buprenorphine-mono product. Neonates were full-term with normal birth parameters. Four neonates were treated for NAS, and number of days treated for NAS and number of hospital days were in line with values reported for the buprenorphine-mono product. Conclusions Findings suggest no obvious significant adverse maternal or neonatal outcomes related to the use of buprenorphine + naloxone for the treatment of opioid dependence during pregnancy. Scientific Significance These initial findings underscore the need for future research to systematically examine the relative safety and effectiveness of buprenorphine + naloxone for mother, fetus, and child.",
author = "Kimber Debelak and Morrone, {William R.} and O'Grady, {Kevin E.} and Jones, {Hendr{\'e}e E.}",
year = "2013",
month = "5",
doi = "10.1111/j.1521-0391.2012.12005.x",
language = "English (US)",
volume = "22",
pages = "252--254",
journal = "American Journal on Addictions",
issn = "1055-0496",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy - Initial patient care and outcome data

AU - Debelak, Kimber

AU - Morrone, William R.

AU - O'Grady, Kevin E.

AU - Jones, Hendrée E.

PY - 2013/5

Y1 - 2013/5

N2 - Background and Objectives Research has indicated that the buprenorphine-mono product yields maternal outcomes similar to methadone and a less severe neonatal abstinence syndrome. However, maternal and neonatal outcomes following buprenorphine + naloxone exposure during pregnancy have not been documented. Methods Retrospective chart review identified 10 opioid-dependent pregnant women treated with the buprenorphine + naloxone film product between January, 2010-June, 2011. Seven maternal outcome measures - weight gain, fetal presentation at delivery, Cesarean delivery, analgesia during delivery, urine drug screening results at delivery, number of days of maternal hospital stay, and began breastfeeding following delivery - and eleven neonatal outcome measures - gestational age at delivery, 1- and 5-minute Apgar scores, head circumference, length, and weight at birth, treated for neonatal abstinence syndrome (NAS), total amount of morphine sulfate needed to treat NAS, length of hospital stay for NAS treatment, and length of hospital stay - were extracted from medical records. Results Maternal findings were unremarkable, and comparable with what might be found following treatment with the buprenorphine-mono product. Neonates were full-term with normal birth parameters. Four neonates were treated for NAS, and number of days treated for NAS and number of hospital days were in line with values reported for the buprenorphine-mono product. Conclusions Findings suggest no obvious significant adverse maternal or neonatal outcomes related to the use of buprenorphine + naloxone for the treatment of opioid dependence during pregnancy. Scientific Significance These initial findings underscore the need for future research to systematically examine the relative safety and effectiveness of buprenorphine + naloxone for mother, fetus, and child.

AB - Background and Objectives Research has indicated that the buprenorphine-mono product yields maternal outcomes similar to methadone and a less severe neonatal abstinence syndrome. However, maternal and neonatal outcomes following buprenorphine + naloxone exposure during pregnancy have not been documented. Methods Retrospective chart review identified 10 opioid-dependent pregnant women treated with the buprenorphine + naloxone film product between January, 2010-June, 2011. Seven maternal outcome measures - weight gain, fetal presentation at delivery, Cesarean delivery, analgesia during delivery, urine drug screening results at delivery, number of days of maternal hospital stay, and began breastfeeding following delivery - and eleven neonatal outcome measures - gestational age at delivery, 1- and 5-minute Apgar scores, head circumference, length, and weight at birth, treated for neonatal abstinence syndrome (NAS), total amount of morphine sulfate needed to treat NAS, length of hospital stay for NAS treatment, and length of hospital stay - were extracted from medical records. Results Maternal findings were unremarkable, and comparable with what might be found following treatment with the buprenorphine-mono product. Neonates were full-term with normal birth parameters. Four neonates were treated for NAS, and number of days treated for NAS and number of hospital days were in line with values reported for the buprenorphine-mono product. Conclusions Findings suggest no obvious significant adverse maternal or neonatal outcomes related to the use of buprenorphine + naloxone for the treatment of opioid dependence during pregnancy. Scientific Significance These initial findings underscore the need for future research to systematically examine the relative safety and effectiveness of buprenorphine + naloxone for mother, fetus, and child.

UR - http://www.scopus.com/inward/record.url?scp=84876920714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876920714&partnerID=8YFLogxK

U2 - 10.1111/j.1521-0391.2012.12005.x

DO - 10.1111/j.1521-0391.2012.12005.x

M3 - Article

C2 - 23617867

VL - 22

SP - 252

EP - 254

JO - American Journal on Addictions

JF - American Journal on Addictions

SN - 1055-0496

IS - 3

ER -